T2 Biosystems (TTOO) Stock Price

T2 Biosystems Price

NASDAQ·CLOSED
0.00
​
Market closed

Revenue has compounded at 71.5% per year over the past 11 years to 7.19 M USD. T2 Biosystems's net margin stands at -696.2%, up from -707.9% several years earlier.

T2 Biosystems stock price

Access this data via the Eulerpool API

T2 Biosystems business model & stock analysis

T2 Biosystems, Inc. engages in the development of proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 151 full-time employees. The company went IPO on 2014-08-07. The firm's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The firm's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The firm offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Frequently asked questions about T2 Biosystems

6 analysts currently rate the T2 Biosystems stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect T2 Biosystems to generate revenue of 33.30 M USD and earnings per share of -4.84 USD.

Converted at the current exchange rate, the T2 Biosystems share trades at 0.00 EUR (0.00 USD).

The T2 Biosystems share (TTOO) is listed on 5 stock exchanges, including: NASDAQ (TTOO), London (0A57.L), Frankfurt (3T2.F), München (3T2.MU), Düsseldorf (3T2.DU).

The expected revenue of T2 Biosystems is 33.30 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of T2 Biosystems is -19.63 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of T2 Biosystems is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the T2 Biosystems stock.

The price-to-sales ratio (P/S) of T2 Biosystems is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the T2 Biosystems stock.

The Eulerpool Quality Score for T2 Biosystems is 3/10.

The ISIN of T2 Biosystems is US89853L3024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of T2 Biosystems is A119H3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of T2 Biosystems is TTOO. The ticker symbol is used to trade T2 Biosystems shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
47,635.76 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Aug 7, 2014
ISIN
US89853L3024
Cusip
89853L104
Sedol
BPN6883
Market capitalization
19,635.00 USDMicro Cap
52-Week Range
PEG
0.00
P/E ratio
P/Ee 2024
—
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-378.00 %
Last updated Oct 10, 2026, 11:02 AM

T2 Biosystems Ticker

DÜSSELDORF · 3T2.DUFRANKFURT · 3T2.FLONDON · 0A57.LMUNICH · 3T2.MUNASDAQ · TTOO